On October 27, 2023, Professor Fan Wang, Director of the Medical Isotope Research Center of Peking University, was invited by Professor Wei-Guo Zhu, Director of the Shenzhen University International Cancer Center, to give seminar titled "Molecular Imaging and Precision Diagnosis and Treatment of Tumor in Nuclear Medicine" at the Shenzhen University Lihu Campus.

Tumor molecular imaging tracers and isotope diagnostic tools are crucial for making an accurate tumor diagnosis and deciding treatment pathways. At present, PET imaging technology is preferred for tumor diagnostics, due to its efficiency in tumor staging and monitoring, but it also has shortcomings. A key constraint is its high cost. A more affordable nuclear medicine tool is SPECT, but unfortunately the tumor imaging drugs are not effective. In her presentation, Professor Fan Wang introduced her research on the development of SPECT imaging drugs. Under her leadership, her research team developed the world's first Integrin receptor imaging agent, which has now completed phase III of clinical trials. Professor Wang also developed a new SPECT imaging instrument that overcomes many of the previous disadvantages to SPECT imaging technology, thus closing the loop from mechanistic research to the development of drug targets and diagnostic equipment. Professor Wang finished by outlining her research in developing tumor drugs with nuclides. After the presentation, she held a lively and informative Q&A session that was enjoyed by all attendees.

Brief introduction of the Speaker

Dr. Fan Wang is a professor at Peking University, Director of the Medical Isotope Research Center of Peking University, visiting professor at the Institute of Biophysics of the Chinese Academy of Sciences, special researcher at the Guangzhou National Laboratory, and chairman of the Imaging Division of the Chinese Biophysical Society. She established the Medical Isotope Research Center of Peking University, which is home to researchers conducting studies on molecular probes, molecular imaging, tumor radiation targeted therapy, diagnostic and therapeutic radiopharmaceuticals. She is the chief scientist of a national "Science and Technology Tackling" project, an "863" project, a national "Major New Drug Creation" project, and a national "Major New Drug Creation" project. In 2011, she was awarded the National Outstanding Young Scientist Fund, making her the first recipient of this award in the field of nuclear medicine in China. Professor Wang has also been recognized with various awards including the Grand Prize for Technological Invention in the 2022 Ministry of Education Award for Outstanding Achievements in Scientific Research in Colleges and Universities (Science and Technology).